Nuvectis Pharma, Inc. (NASDAQ: NVCT) is now covered by analysts at Maxim Group. They set a "buy" rating and a $17.00 price target on the stock.
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is now covered by analysts at Laidlaw. They set a "buy" rating and a $19.00 price target on the stock.
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation